Objective and subjective measures of dalfampridine efficacy in clinical practice
Sylvia Klineova(Icahn School of Medicine at Mount Sinai), Stephen Krieger(Icahn School of Medicine at Mount Sinai), Fred Lublin(Icahn School of Medicine at Mount Sinai), Colleen Farrell(University of Utah), Joshua Friedman(Icahn School of Medicine at Mount Sinai), Rebecca Straus Farber(Icahn School of Medicine at Mount Sinai)
Multiple Sclerosis Journal - Experimental Translational and Clinical
July 1, 2018
Cited by 4
Related Papers
How patients with multiple sclerosis acquire disability
|Brain|2022|508
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
|Neuro-Oncology|2020|44
Quantitative MRI studies for assessment of multiple sclerosis
|Magnetic Resonance in Medicine|1992|43
Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma
|Neuro-Oncology Advances|2022|28
Open-label, add-on trial of cetirizine for neuromyelitis optica
|Neurology Neuroimmunology & Neuroinflammation|2018|26